Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Hikma Has Strong Growth Potential, But High Expectations

Anglo-Jordanian Hikma Pharmaceuticals plc (OTCPK:HKMPY) has had some curious ups and downs over the past two years. The company contemplated selling its injectables business (and got bids) only to decide to keep it, and the company's U.S. oral generics business was hurt by a warning letter in 2012 only to see a shortage of doxycycline in the U.S. lead to significant revenue and profit growth.

Hikma is going to be hard-pressed to maintain that momentum in doxycycline, but this remains a business with some strong growth potential. Not only is Hikma looking to leverage its position as the leading local manufacturer of branded generics for the Middle East and North African markets, but the company has begun to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details